These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
269 related articles for article (PubMed ID: 33522880)
1. Medications for Idiopathic Pulmonary Fibrosis: IPF Part 2. Guler SA; Lindell KO; Swigris J; Ryerson CJ Am J Respir Crit Care Med; 2021 Feb; 203(3):P7-P8. PubMed ID: 33522880 [No Abstract] [Full Text] [Related]
2. Novel treatments for idiopathic pulmonary fibrosis. Spagnolo P Am J Med; 2015 May; 128(5):447-9. PubMed ID: 25613299 [No Abstract] [Full Text] [Related]
3. Design of Idiopathic Pulmonary Fibrosis Clinical Trials in the Era of Approved Therapies. Kaner RJ; Bajwa EK; El-Amine M; Gorina E; Gupta R; Lazarus HM; Luckhardt TR; Mouded M; Posada K; Richeldi L; Stauffer J; Tutuncu A; Martinez FJ Am J Respir Crit Care Med; 2019 Jul; 200(2):133-139. PubMed ID: 30985215 [No Abstract] [Full Text] [Related]
4. Two therapies now available for idiopathic pulmonary fibrosis. Morrow T Manag Care; 2014 Dec; 23(12):47-8. PubMed ID: 25939185 [No Abstract] [Full Text] [Related]
5. Therapeutic targets in idiopathic pulmonary fibrosis. Kolb M; Bonella F; Wollin L Respir Med; 2017 Oct; 131():49-57. PubMed ID: 28947042 [TBL] [Abstract][Full Text] [Related]
6. The earlier, the better: Impact of early diagnosis on clinical outcome in idiopathic pulmonary fibrosis. Aiello M; Bertorelli G; Bocchino M; Chetta A; Fiore-Donati A; Fois A; Marinari S; Oggionni T; Polla B; Rosi E; Stanziola A; Varone F; Sanduzzi A Pulm Pharmacol Ther; 2017 Jun; 44():7-15. PubMed ID: 28257817 [TBL] [Abstract][Full Text] [Related]
8. POINT: Should All Patients With Idiopathic Pulmonary Fibrosis, Even Those With More Than Moderate Impairment, Be Treated With Nintedanib or Pirfenidone? Yes. King CS; Nathan SD Chest; 2016 Aug; 150(2):273-5. PubMed ID: 27292047 [No Abstract] [Full Text] [Related]
9. COUNTERPOINT: Should All Patients With Idiopathic Pulmonary Fibrosis, Even Those With More Than Moderate Impairment, Be Treated With Nintedanib or Pirfenidone? No. Brown KK Chest; 2016 Aug; 150(2):276-8. PubMed ID: 27292046 [No Abstract] [Full Text] [Related]
11. Patient and site characteristics associated with pirfenidone and nintedanib use in the United States; an analysis of idiopathic pulmonary fibrosis patients enrolled in the Pulmonary Fibrosis Foundation Patient Registry. Holtze CH; Freiheit EA; Limb SL; Stauffer JL; Raimundo K; Pan WT; Flaherty KR; Kim HJ Respir Res; 2020 Feb; 21(1):48. PubMed ID: 32041621 [TBL] [Abstract][Full Text] [Related]
12. Naloxegol oxalate, pirfenidone, and nintedanib. Hussar DA; Jeon MM J Am Pharm Assoc (2003); 2015; 55(4):461-3. PubMed ID: 26161491 [No Abstract] [Full Text] [Related]
13. Therapeutic advances in idiopathic pulmonary fibrosis. George G; Vaid U; Summer R Clin Pharmacol Ther; 2016 Jan; 99(1):30-2. PubMed ID: 26502087 [No Abstract] [Full Text] [Related]
14. Current approaches to the management of idiopathic pulmonary fibrosis. Raghu G; Richeldi L Respir Med; 2017 Aug; 129():24-30. PubMed ID: 28732832 [TBL] [Abstract][Full Text] [Related]
15. Forced vital capacity in idiopathic pulmonary fibrosis--FDA review of pirfenidone and nintedanib. Karimi-Shah BA; Chowdhury BA N Engl J Med; 2015 Mar; 372(13):1189-91. PubMed ID: 25806913 [No Abstract] [Full Text] [Related]
16. Clinical trial research in focus: why do so many clinical trials fail in IPF? Spagnolo P; Maher TM Lancet Respir Med; 2017 May; 5(5):372-374. PubMed ID: 28412184 [No Abstract] [Full Text] [Related]
18. Hot off the breath: A big step forward for idiopathic pulmonary fibrosis. Ryerson CJ; Collard HR Thorax; 2014 Sep; 69(9):791-2. PubMed ID: 24996636 [No Abstract] [Full Text] [Related]
19. [Antifibrotic treatment]. von der Beck D; Löh B; Drakopanagiotakis F; Markart P; Günther A Dtsch Med Wochenschr; 2014 Dec; 139(49):2523-5. PubMed ID: 25423462 [No Abstract] [Full Text] [Related]